Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | HRH2 | P25021 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL576359 | 0.94 | CHRNB4 (0.35) | ALDH1A1CYP11B2TSHRCHRNB4CHRNA3 | |
| SCHEMBL2537360 | 0.86 | ALDH1A1 (0.36) | ALDH1A1CYP11B2CHRNB4CHRNA3 | |
| SCHEMBL28911580 | 0.76 | HRH3 (0.46) | ALDH1A1HRH2HRH3 | |
| SCHEMBL4607832 | 0.74 | ALDH1A1 (0.33) | ALDH1A1ALOX15TSHRCHRNB4CHRNA3 | |
| SCHEMBL5485555 | 0.74 | ALDH1A1 (0.36) | ALDH1A1CYP11B2ALOX15TSHRCHRNB4 | |
| SCHEMBL17652437 | 0.74 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL15758247 | 0.72 | IGF1R (0.46) | ALDH1A1ALOX15 | |
| SCHEMBL11504128 | 0.71 | DDB1 (0.42) | ALDH1A1 | |
| SCHEMBL16817775 | 0.71 | MAPT (0.41) | ALDH1A1ALOX15TSHR | |
| SCHEMBL7700085 | 0.70 | CHRNB4 (0.41) | ALDH1A1CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372854-B2 | Pyrrolo[2,3-D]pyrimidine compounds | PFIZER INC. (US) | 2013-02-12 | — | — | US | claimed |
| EP-2513114-A1 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS | Pfizer Inc. (US) | 2012-10-24 | — | — | EP | claimed |
| US-20110294826-A1 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2011-12-01 | — | — | US | claimed |
| WO-2011075334-A1 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2011-06-23 | — | — | WO | claimed |
| WO-2010131147-A1 | CYCLOBUTENEDIONE DERIVATIVES | PFIZER LIMITED (GB) | 2010-11-18 | — | — | WO | claimed |
| WO-2010131145-A1 | CYCLOBUTENEDIONE DERIVATIVES | PFIZER LIMITED (GB) | 2010-11-18 | — | — | WO | claimed |
| WO-2010131146-A1 | CYCLOBUTENEDIONE DERIVATIVES | PFIZER LIMITED (GB) | 2010-11-18 | — | — | WO | claimed |
| US-8372854-B2 | Pyrrolo[2,3-D]pyrimidine compounds | PFIZER INC. (US) | 2013-02-12 | — | — | US | disclosed |
| EP-2513114-A1 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS | Pfizer Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20110294826-A1 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-8044075-B2 | IL-8 receptor antagonists | GLAXOSMITHKLINE (US) | 2011-10-25 | — | — | US | disclosed |
| WO-2011075334-A1 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20100298387-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2010-11-25 | — | — | US | disclosed |
| WO-2010131145-A1 | CYCLOBUTENEDIONE DERIVATIVES | PFIZER LIMITED (GB) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010131146-A1 | CYCLOBUTENEDIONE DERIVATIVES | PFIZER LIMITED (GB) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010131147-A1 | CYCLOBUTENEDIONE DERIVATIVES | PFIZER LIMITED (GB) | 2010-11-18 | — | — | WO | disclosed |
| EP-2099300-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008070707-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298387-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | ALDH1A1 2969/4885CYP11B2 864/4885ALOX15 802/4885 |
| US-20110294826-A1 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS | JAK3, JAK1, JAK2 | ALDH1A1 2934/4885CYP11B2 2202/4885ALOX15 2670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.